Navigation Links
Intercept Pharmaceuticals to Collaborate With NIDDK on Study of Obeticholic Acid (INT-747) in Nonalcoholic Steatohepatitis (NASH)
Date:7/28/2010

Mark Pruzanski, MD, founder, President and CEO of Intercept, commented, "We are excited to collaborate with the NIDDK and CRN to test our drug in such a robust NASH study.  Last year we presented data showing that obeticholic acid improved insulin sensitivity, lowered liver enzymes and induced weight loss in type 2 diabetic patients with NAFLD. These results and the novel mechanism of action of our drug are a promising basis for pursuing NASH."  

Pat Robuck, PhD, MPH, the senior advisor for clinical trials in digestive and liver diseases, in the NIDDK's Division of Digestive Diseases and Nutrition, stated, "There is a huge unmet medical need in this patient population. The NIDDK, working together with our NASH CRN investigators, is committed to discovering effective and safe treatments for this serious disease.  The preclinical and clinical data obtained so far with obeticholic acid suggest that it has beneficial effects on glucose metabolism and the liver, and the NASH CRN steering committee thinks it warrants rigorous clinical evaluation in NASH."

About Obeticholic Acid (INT-747)

Obeticholic acid is a potent, first-in-class farnesoid X receptor (FXR) agonist derived from the primary human bile acid chenodeoxycholic acid, the natural endogenous FXR agonist.  Previously known as INT-747, the drug was recently given the generic name of obeticholic acid.  In 2009, the company announced two sets of positive Phase II results from studies in type 2 diabetics with NAFLD and in patients with refractory primary biliary cirrhosis (PBC). These data support obeticholic acid's potential as a novel, hepatoprotective agent in a broad range of chronic liver diseases. Intercept currently plans to advance obeticholic acid into Phase III for PBC, while pursuing addition
'/>"/>

SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intercept Pharmaceuticals Raises $25 Million Series B Financing
2. Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
3. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
4. HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing
5. Amylin Pharmaceuticals to Present at the Wedbush Life Sciences Conference 2010
6. Foundation Venture Capital Group Sells Interest in Longevica Pharmaceuticals
7. Onyx Pharmaceuticals Announces Positive Top-Line Carfilzomib Data From Phase 2b Study
8. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide a Clinical Update on Carfilzomib
9. Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors
10. Poniard Pharmaceuticals Receives NASDAQ Deficiency Notice Related to Minimum Bid Price
11. Bayer HealthCare Pharmaceuticals Supports New Jersey Governors School in the Sciences at Drew University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 Cynosure, Inc. (Nasdaq: ... light-based aesthetic treatment systems for high-volume applications, today reported ... 2014. Second-quarter 2014 financial results incorporate the acquisition of ... 2013. Second-Quarter 2014 Financial Highlights ... $72.6 million , Non-GAAP net income of $7.1 ...
(Date:7/29/2014)... Texas , July 29, 2014  Novation, ... new web-based applications with breakthrough interactive features that ... workflows for members of Children,s Hospital Association.  ... the Novation Optimize Solutions umbrella – Value Analysis, ... how Novation helps organizations address the most critical ...
(Date:7/29/2014)... July 29, 2014  The BioFusionary Corporation, Inc. ... a proprietary electromagnetic induction platform with aesthetic and ... agreement under which TBC will merge with ... in an all-stock transaction. Upon completion ... on the Australian Stock Exchange under the code ...
Breaking Medicine Technology:Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 2Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 3Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 4Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 5The BioFusionary Corporation, Inc. Announces Intent To Complete Reverse Takeover Of Australia-Based Continuation Investments Limited 2The BioFusionary Corporation, Inc. Announces Intent To Complete Reverse Takeover Of Australia-Based Continuation Investments Limited 3
... WOODCLIFF LAKE, N.J., Nov. 3, 2010 Par Pharmaceutical Companies, ... the third quarter ended September 30, 2010. For ... total revenues of $234.4 million and income from continuing operations ... included a $2.0 milestone payment to Tris Pharma, Inc., a ...
... 2010 Regado Biosciences, Inc., a privately held company ... agents, announced that Steven L. Zelenkofske, D.O., F.A.C.C., Senior ... at the American College of Chest Physicians (ACCP) Coagulation ... Vancouver, BC, Canada.  The abstract is titled "Sustained Inhibition ...
Cached Medicine Technology:Par Pharmaceutical Companies Reports Third Quarter 2010 Results 2Par Pharmaceutical Companies Reports Third Quarter 2010 Results 3Par Pharmaceutical Companies Reports Third Quarter 2010 Results 4Par Pharmaceutical Companies Reports Third Quarter 2010 Results 5Par Pharmaceutical Companies Reports Third Quarter 2010 Results 6Par Pharmaceutical Companies Reports Third Quarter 2010 Results 7Par Pharmaceutical Companies Reports Third Quarter 2010 Results 8Par Pharmaceutical Companies Reports Third Quarter 2010 Results 9Par Pharmaceutical Companies Reports Third Quarter 2010 Results 10Par Pharmaceutical Companies Reports Third Quarter 2010 Results 11Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010 2Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010 3
(Date:7/29/2014)... Calif. (PRWEB) July 29, 2014 July ... drug abuse directly at the source? That’s the big ... an innovative prescription drug abuse risk program developed by ... hundreds of applicants worldwide to be part of ... 10-12 in San Francisco, CA. The Hive is a ...
(Date:7/29/2014)... should significantly reform the federal system for financing ... the public,s $15 billion annual investment is producing ... new report by the Institute of Medicine. ... requires little accountability, allocates funds independent of workforce ... to train physicians in the health care settings ...
(Date:7/29/2014)... HealthDay Reporter MONDAY, July 28, 2014 ... to rage throughout West Africa poses little risk to Americans, ... physical touch, and it can,t be spread by people who ... the National Center for Emerging & Zoonotic Infectious Diseases at ... a Monday afternoon news conference. Those factors -- and ...
(Date:7/29/2014)... July 29, 2014 – Silverado, a provider of ... announce that it is a Bronze winner in the 35th ... Silverado Through a Child's Eye and Silverado Resident ... Through a Child's Eye , seven-year-old Mia Sandoval shares her ... Place, a memory care community in Los Angeles. The feel-good ...
(Date:7/29/2014)... July 29, 2014 Doug and Sandra Williams ... years and selling their grow-your-own log kits for almost that ... Williams’ diet and a treat for their guests. A ... perspective to the Lost Creek Mushroom Farm online coverage. , ... chefs, but soon turned to selling the logs instead of ...
Breaking Medicine News(10 mins):Health News:SafeUseNow Selected to Showcase at TEDMED Hive 2014 2Health News:SafeUseNow Selected to Showcase at TEDMED Hive 2014 3Health News:$15 billion annual public funding system for doctor training needs overhaul, says IOM 2Health News:$15 billion annual public funding system for doctor training needs overhaul, says IOM 3Health News:CDC Downplays Ebola's Threat to the United States 2Health News:CDC Downplays Ebola's Threat to the United States 3Health News:CDC Downplays Ebola's Threat to the United States 4Health News:Silverado Selected a Winner in the 35th Annual Telly Awards for Producing Inspiring Online Video Content 2Health News:Lost Creek Mushroom Farm Cooks Up a Company Dish from Shiitake Mushrooms Grown on Logs With Grow-Your-Own Log Kits 2Health News:Lost Creek Mushroom Farm Cooks Up a Company Dish from Shiitake Mushrooms Grown on Logs With Grow-Your-Own Log Kits 3Health News:Lost Creek Mushroom Farm Cooks Up a Company Dish from Shiitake Mushrooms Grown on Logs With Grow-Your-Own Log Kits 4
... ... aftershave, beard inhibitor, and SPF29 sun block spray. , ... (PRWEB) January 27, 2010 -- Hey Dude Skin Care ™, ... an outstanding array of premium skin care products targeted at the unique protection, repair and ...
... CHAIRMAN , NEW YORK , Jan. 27 ... University announced today that William H. Foster , PhD, Dean ... Service, will become President and Chief Executive Officer of CASA on ... former U.S. Secretary of Health, Education, and Welfare who founded CASA in ...
... , , PHOENIX ... Eating and Anxiety Disorders ( http://www.remudaranch.com ) and MASK (Mothers ... teachers and students about eating disorders and related issues. , ... trained by an organization of the caliber of Remuda Ranch," ...
... , , NEW YORK , Jan. 27 ... $250,000 grant to the Clinton Health Access Initiative (CHAI), a ... in 2002. The grant will ensure the continuation of HIV/AIDS ... of the devastating January 12 earthquake. , ...
... , , LOS ANGELES , Jan. 27 ... more information about the IDEAL breast implants on his blog. He discussed ... would be available to the public for a clinical trial. , Board-certified ... of the new IDEAL breast implants. These implants are known to have ...
... woman who suggests using a condom makes no difference to ... suggests it makes a difference. If she highlights her sexuality ... and fun activity, other women judge her more harshly than ... or shares her concerns about sexually transmitted infections. Dr. Michelle ...
Cached Medicine News:Health News:Hey Dude Skin Care™ Rolls Out Line of Premium Men's Skin Care Products 2Health News:William H. Foster Succeeds Califano as President and CEO of CASA* 2Health News:William H. Foster Succeeds Califano as President and CEO of CASA* 3Health News:William H. Foster Succeeds Califano as President and CEO of CASA* 4Health News:Remuda Ranch, Programs for Eating and Anxiety Disorders, and MASK (Mothers Awareness on School-Age Kids), Partner to Help Educate Parents, Teachers and Students About Eating Disorders 2Health News:Remuda Ranch, Programs for Eating and Anxiety Disorders, and MASK (Mothers Awareness on School-Age Kids), Partner to Help Educate Parents, Teachers and Students About Eating Disorders 3Health News:Ford Foundation Commits $250,000 to Support HIV/AIDS Services in Haiti 2Health News:Dr. Jay Calvert MD Announces Details on New Patent-Protected Investigational Breast Implants 2Health News:Dr. Jay Calvert MD Announces Details on New Patent-Protected Investigational Breast Implants 3Health News:Condom or no condom? It's not what you say, it's how you say it 2
... Certified by an independent laboratory ... of Federal Standard 209E. Ergonomic ... fatique and back injuries. Clean ... requirements. Static-control chairs feature dissipative ...
... SCE offers a full line of ... manufacturing and laboratory environments. Every SCE product ... / safety requirements. Now you can have ... hazardous acid / corrosive chemicals and materials ...
... Genie is an all-in-one rotator/rocker with ... five different mixing motions: rotating, ... well as a combination of all ... portion of the Vibraotme Roto-Shake Genie ...
... 55S Rocking Shaker provides the exact ... membranes. The very slow to fast ... tilt provide a gentle wave motion ... and blotted membranes to achieve faster, ...
Medicine Products: